2Saito S,Yamanaka J,Miura K,et al.A novel 3D hepatectomy simulation based on liver circulation:application to liver resection and transplantation.Hepatology,2005,41 (6):1297-1304.
3Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparisonof Fluorine- 18F luorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous cell carcinoma[J]. J Nucl Med,1995, 36(10): 1747-1757.
4Rahn AN, Baum RP, Adamietz IA, et al. Value of 18F-fluorodeoxyglucose positron emission tomography in radiotherapyplanning of head-neck tumors [J]. Strahlenther Onkol, 1998, 174(7): 358-364.
5Nishioka T, Shiga T, Shirato H, et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas [J]. Int J Radiat Oncol Biol Phys, 2002,53(4): 1051-1057.
6Ten Haken R, Thornton A, Sandler H, et al. A quantitative assessment of the addition of MRI to CT-based 3D treatment planning of brain tumors[J]. Radiother Oncol, 1992, 25(9): 121-133.
7Khoo V, Adams E, Saran F, et al. A comparison of clinical target volumes determined by CT and MRI for the radiotherapy planning of base of skull meningiomas[J]. Int J Radiat Oncol Biol Phys, 2000,46(5): 1309-1317.
8Weltens C, Menten J, Feron M, et al. Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging[J]. Radiother Oncol, 2001, 60 (1): 49-59.
9Sannazzari GL, Ragona R, Redda MG, et al. CT-MRI inage fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer[J]. Br J Radiol,2002, 75 (895): 603-607.
10Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study[J]. Int J Radiat Oncol Biol Phys,2003, 57(3): 853-863.
6EP12-A2 User Protocol for Evaluation of Qualitative Test Performance.Approved Guideline-Second Edition[S].2008.
7EP15-A2 User Verification of Performance for Precision and Trueness.Approved Guideline-Second Edition[S].2006.
8MM03-Ed3 Molecular Diagnostic Methods for Infectious Diseases.3rd Edition[S].2015.
9MM01-A3 Molecular Methods for Clinical Genetics and Oncology Testing.Approved Guideline-Third Edition[S].2012.
10U.S.Food and Drug Administration.Class II Special Controls Guideline:Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens -Guideline for Industry and Food and Drug Administration Staff[EB/OL].[2016-06-21].http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm357617.htm.
